Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst

Key Points

• Zacks Research raised Tonix Pharmaceuticals’ Q3 2026 EPS estimate to a loss of $2.50 per share from a previous loss estimate of $2.63. The analyst expects full-year 2026 earnings of negative $10.03 per share.
• Analyst sentiment remains mixed but leans positive overall: Tonix has a consensus “Buy” rating and a $24.50 price target, despite ratings ranging from “Strong Buy” to “Sell.”
• Tonix’s shares opened at $12.83, while the company recently reported a better-than-expected quarterly loss of $2.44 per share and $13.54 million in revenue. CEO Seth Lederman and institutional investors have also recently purchased shares.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for Tonix Pharmaceuticals in a research report issued to clients and investors on Wednesday, September 2nd. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($2.50) per share for the quarter, up from their prior estimate of ($2.63). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($10.03) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals' Q4 2026 earnings at ($2.28) EPS, FY2026 earnings at ($10.03) EPS, FY2027 earnings at ($5.48) EPS and FY2028 earnings at $1.86 EPS.

A number of other equities analysts have also recently issued reports on TNXP. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 29th. Raymond James Financial reiterated a "strong-buy" rating and issued a $27.00 price target on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings cut Tonix Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.50.

Tonix Pharmaceuticals Stock Down 2.5%

Shares of TNXP opened at $12.83 on Thursday. The stock has a market cap of $220.03 million, a price-to-earnings ratio of -0.99 and a beta of 1.74. Tonix Pharmaceuticals has a 12 month low of $9.40 and a 12 month high of $31.55. The company has a 50-day moving average price of $12.13 and a two-hundred day moving average price of $12.87.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.99%. The firm had revenue of $13.54 million for the quarter, compared to analyst estimates of $7.72 million.

Insider Buying and Selling

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 2,000 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $13.79 per share, with a total value of $27,580.00. Following the acquisition, the chief executive officer directly owned 11,005 shares of the company's stock, valued at approximately $151,758.95. This trade represents a 22.21% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders purchased 4,415 shares of company stock worth $55,108. 2.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TNXP. Royal Bank of Canada bought a new position in shares of Tonix Pharmaceuticals in the first quarter valued at about $610,000. Geode Capital Management LLC grew its holdings in Tonix Pharmaceuticals by 182.4% during the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company's stock worth $6,305,000 after acquiring an additional 113,175 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $129,000. Legal & General Group Plc bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $25,000. Finally, New York State Common Retirement Fund bought a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $104,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.